Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer

F Gonzalvez, S Vincent, TE Baker, AE Gould, S Li… - Cancer Discovery, 2021 - AACR
Most EGFR exon 20 insertion (EGFR ex20ins) driver mutations in non–small cell lung
cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To …
被引用次数：131 相关文章

Mobocertinib (TAK-788): A Targeted Inhibitor ofEGFRExon 20 Insertion Mutants in Non–Small Cell Lung Cancer

F Gonzalvez, S Vincent, TE Baker, AE Gould, S Li… - Cancer …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title/>< jats: p> Most EGFR exon 20
insertion (EGFRex20ins) driver mutations in non–small cell lung cancer (NSCLC) are …

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer

F Gonzalvez, S Vincent, TE Baker… - Cancer …, 2021 - pubmed.ncbi.nlm.nih.gov
Most EGFR exon 20 insertion (EGFRex20ins) driver mutations in non-small cell lung cancer
(NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To address the …

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer.

F Gonzalvez, S Vincent, TE Baker, AE Gould, S Li… - Cancer …, 2021 - europepmc.org
Most EGFR exon 20 insertion (EGFRex20ins) driver mutations in non-small cell lung cancer
(NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To address the …